FDA Approves Otsuka's Symtrio, First Triple Inhibitor for ADHD

The U.S. Food and Drug Administration (FDA) has granted approval to Otsuka Pharmaceutical's 'Symtrio,' marking it as the first triple inhibitor for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). This regulatory decision follows a priority review that was initiated in January 2026, with the Prescription Drug User Fee Act (PDUFA) target action date for centanafadine having been set for July 24, 2026.